How to Verify Peptide Therapy Safety: Red Flags, COA Checks, and a Provider Checklist

The Problem With a Bargain-Priced Vial

You’ve done the research. You’ve read about semaglutide’s effect on appetite regulation, or perhaps about BPC-157’s proposed role in gut repair, or growth hormone secretagogues for body composition. The clinical literature is compelling. Then you find it: a website selling the compound you’ve been researching, at a fraction of the clinic price, no prescription required.

This is where most patients make a mistake that no amount of prior research can undo. They equate access with legitimacy.

The peptide therapy market has expanded rapidly, accelerated by GLP-1 enthusiasm and growing interest in precision metabolic care. The FDA issued multiple warning letters to compounding pharmacies between 2024 and 2025 for selling adulterated or subpotent versions of semaglutide.¹ A significant share of “research-grade” peptide products sold online have been found to miss purity benchmarks or contain unlisted contaminants.² The clinical concern is not that peptides are inherently dangerous — it’s that unverified peptides can be.

This guide walks through how to verify peptide therapy safety before committing to any protocol. If you’re new to the space, start with Meto’s beginner’s guide to peptides and metabolic health before continuing — it provides the biological context that makes the following verification steps much more meaningful.

What “Legitimate” Peptide Therapy Actually Means

Before evaluating any provider, you need a working definition of clinical legitimacy — because in this space, it is not binary.

The regulatory landscape, plainly stated

Most therapeutic peptides exist in a nuanced regulatory position. FDA-approved injectables like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have cleared the full drug approval process. Compounded versions of these — and other peptides such as sermorelin, BPC-157, and CJC-1295 — are produced under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.³ This framework permits licensed compounding pharmacies to prepare customized medications outside the standard approval pathway, under specific conditions and state board oversight.

Compounded does not mean counterfeit. A properly licensed 503A pharmacy operating under accreditation and state oversight is a legitimate clinical source. An unregistered international vendor labeling products “not for human use” is not — and that disclaimer provides no legal or biological protection to the end user.

The FDA’s advisory review of several compounded peptides is ongoing. Meto’s article on the FDA July 2026 peptide advisory meeting covers what patients need to understand about access and approval status in real time.

The three-part legitimacy test

Any peptide provider worth working with should satisfy all three of the following simultaneously:

• Sourcing — the compound originates from an accredited, licensed compounding pharmacy
• Oversight — a licensed provider prescribes, monitors, and adjusts your protocol
• Documentation — purity is independently verified through a third-party Certificate of Analysis

If one pillar is missing, the other two don’t compensate.

How to Verify a Peptide Provider: Step by Step

1. Confirm that a prescription is required. No prescription requirement is the clearest possible signal that you are not dealing with a regulated clinical source. Any peptide used for metabolic or hormonal purposes — regardless of FDA approval status — should be gated behind a real medical evaluation. If you can add a compound to a checkout cart without speaking to anyone with a medical licence, stop there.
2. Verify the compounding pharmacy’s accreditation. Ask the provider which pharmacy fulfils their prescriptions, then verify it independently. The Pharmacy Compounding Accreditation Board (PCAB) maintains a public directory of accredited pharmacies in the US.⁴ PCAB accreditation indicates adherence to USP standards for sterile preparation, testing protocols, and documentation requirements. If your provider uses a 503B outsourcing facility, verify its registration through the FDA’s registered outsourcing facilities database.⁵
3. Request and evaluate a Certificate of Analysis (COA). A legitimate provider will share a COA without hesitation. If there is friction, deflection, or a claim that testing documentation is proprietary, treat this as a hard stop. What to look for in a COA is covered in full in the section below.
4. Evaluate the clinical oversight model. There should be a named, licensed prescriber attached to your care — verifiable through the relevant state medical board. Ask specifically about the monitoring protocol: are follow-up labs included? At what intervals? What is the process if you report a side effect? A provider who disappears after issuing a prescription is not providing clinical oversight. They are providing bureaucratic cover for a sale.
5. Assess the quality of the consultation itself. A genuine clinical consultation includes a review of medical history, contraindication screening, baseline labs ordered before or concurrent with treatment, and a written dosing protocol with defined follow-up checkpoints. A consult that takes less than ten minutes and ends with a prescription and a shipping confirmation is not clinical care. See Meto’s guide on why lab work matters before starting any metabolic program for the baseline testing a responsible prescriber should initiate.
6. Evaluate transparency around risk. A clinician who discusses only the upside of a peptide protocol is not being complete with you. Legitimate providers discuss contraindications, known adverse effects, drug interactions, and the limits of current evidence — which for many compounded peptides are meaningful. Informed consent is the mechanism through which clinical accountability exists.

Peptide Provider Red Flags: 8 Signs That Should Stop You

These are not technicalities. Each one represents a meaningful clinical or legal failure.

1. No prescription required. This is the most consistent marker of an unregulated source. There are no exceptions.
2. No COA available — or a COA from the manufacturer’s own lab. Self-certified testing is not third-party testing. The entity producing the compound cannot objectively verify it.
3. Marketing language using terms like “cure,” “guaranteed,” or “no side effects.” These are FDA-prohibited in drug marketing for a reason.⁶ Peptide therapy, even when clinically appropriate, carries no such certainties.
4. Pricing dramatically below the clinical market range. Pharmaceutical-grade peptide production, sterile compounding, and independent testing carry real costs. When prices are inexplicably low, something in that chain has almost certainly been cut.
5. International shipping with no clinical oversight. Importing compounded prescription substances without a legitimate prescription and proper import documentation is a legal exposure — not just a quality concern.
6. No verifiable licensed provider on the platform. Some online “clinics” have no named, licensable physician of record. This is not telemedicine — it is a storefront.
7. No monitoring protocol offered. A peptide affecting insulin secretion, gastric emptying, or IGF-1 signalling requires structured lab follow-up. A provider who doesn’t offer it has not thought past the transaction.
8. No physical address, contact details, or licensing disclosure on the website. Legitimate medical operations are legally required to be locatable and accountable.

How to Read a Certificate of Analysis for Peptides

A Certificate of Analysis is the document that tells you what is actually in the vial. It is not a product brochure. It is a lab report, and it should read like one.

What a legitimate COA must contain

• Purity percentage — confirmed via high-performance liquid chromatography (HPLC). The accepted clinical standard for therapeutic peptides is ≥98% purity.⁷
• Identity confirmation — via mass spectrometry (MS), verifying that the peptide sequence matches what was ordered, not merely that a peptide-like substance is present
• Heavy metals panel — lead, arsenic, mercury, cadmium, governed by USP General Chapter <232> on elemental impurities⁸
• Endotoxin testing — bacterial endotoxins can cause severe pyrogenic reactions; sterile preparations must meet limits under USP General Chapter <85>⁹
• Moisture content
• Lot number traceable to your specific batch — a COA without a matching lot number cannot be verified against what you received

Who should issue it

The issuing laboratory must be independent of the manufacturer, and ideally accredited to ISO/IEC 17025 — the international benchmark for testing and calibration laboratory competence.¹⁰ If the COA is signed by the compounding pharmacy itself rather than an external accredited laboratory, it does not constitute independent verification.

Peptide Prescription Requirements: What to Expect From a Legitimate Clinic

Which peptides require a prescription

Semaglutide and tirzepatide are unambiguously prescription-only. Sermorelin — a growth hormone-releasing hormone analogue — also requires a prescription. Peptides such as BPC-157, TB-500, and AOD-9604 are not FDA-approved for human use but are compounded and prescribed off-label in clinical settings, occupying a regulatory gray zone that is actively under review.

The point is not that a prescription makes a compound safe — it’s that a prescription situates you inside a clinical relationship with someone legally and ethically accountable for what happens next. Purchasing outside that structure removes that accountability entirely. Meto’s article on compounded semaglutide and the FDA’s 2026 crackdown provides important context on how rapidly this landscape is shifting.

What a legitimate prescribing process looks like

A properly structured peptide consultation — whether via telehealth or in person — includes a clinical encounter with a licensed provider, baseline labs before or concurrent with the prescription, a written protocol specifying dose, frequency, and administration, and a defined follow-up timeline (typically four to six weeks for most metabolic peptides). If you’re trying to determine which GLP-1 compound fits your metabolic picture, Meto’s guide on using lab results to choose between semaglutide and tirzepatide walks through the biomarker logic that should guide that conversation.

Peptide Therapy Safety Checklist: 12 Questions Before You Start

Apply this checklist to any provider or protocol you’re considering. Every answer should be yes.

About the provider and process:

• Is a valid prescription required to access this compound?
• Is there a named, licensed prescriber verifiable via state medical board?
• Did the consultation include a health history review and contraindication screening?
• Was a baseline lab panel ordered or reviewed before the prescription was issued?
• Were potential side effects and contraindications explicitly discussed?
• Is there a written follow-up protocol with defined intervals?

About the compound and its sourcing:

• Is the compound sourced from a PCAB-accredited or state-licensed compounding pharmacy?
• Has the provider shared a COA for my specific product batch?
• Is the COA issued by an independent, ISO/IEC 17025-accredited laboratory?
• Does the COA include purity %, identity confirmation, heavy metals, and endotoxin results?
• Does the lot number on the COA match the lot number on my vial?
• Is the compound stored and shipped under validated cold-chain conditions?

If any item remains unchecked after your due diligence, that gap warrants a direct conversation with your provider before you proceed — not reassurance-seeking, but a specific answer.

Meto’s Position: Why Provider Quality Is Non-Negotiable

The clinical interest in peptide therapy for metabolic health is well-founded. GLP-1 receptor agonists have meaningfully changed the treatment landscape for obesity and insulin resistance.¹¹ Growth hormone secretagogues have a legitimate place in discussions around metabolic aging and body composition. The science behind these compounds is not fringe — much of it is published in peer-reviewed journals and supported by clinical trial data.

What concerns us is the infrastructure gap between that legitimate interest and how many patients are currently accessing these compounds. The unregulated peptide market has expanded precisely because clinical access can feel slow, expensive, or opaque — and a parallel economy has filled that gap with sources that meet none of the quality standards described above.

Patients shouldn’t have to become credentialing experts to access safe care. That’s the provider’s job.

Every provider on Meto is licensed, board-certified, and accountable to a state medical board. 

Consultations are structured around your actual clinical picture. Prescriptions, where clinically appropriate, go through accredited compounding pharmacies. Follow-up labs and check-ins aren’t optional extras — they’re built into the care model.

If you’re exploring peptide therapy for weight management, insulin resistance, hormonal health, or any metabolic concern, the starting point isn’t sourcing a compound — it’s a conversation with a provider who can tell you whether a given peptide is appropriate for your biology, what the evidence actually supports, and how to monitor your response.

→  Connect with a licensed Meto provider: app.meto.co/quiz

The Bottom Line

Verifying peptide therapy safety isn’t an expression of distrust toward the science. Peptides are legitimate tools in metabolic medicine, and their clinical applications are expanding. The question is whether the specific compound in your vial was manufactured correctly, tested independently, prescribed by someone who knows your health history, and monitored by someone who will notice — and act — if something goes wrong.

That is not a high bar. It is the minimum standard for any medical intervention.

The checklist above takes fifteen minutes to work through. The consequences of skipping it can take considerably longer to resolve.

Frequently Asked Questions

Is it legal to buy peptides online without a prescription?

In the US, compounds with clinical intent — including most peptides used in metabolic or hormonal health — require a prescription when sold as medications. Vendors that circumvent this through “not for human use” or “research only” labelling are operating in a legal gray zone that provides no protection if a product causes harm.

How do I know if a peptide is pharmaceutical grade?

The clearest verification is a COA from an independent, ISO/IEC 17025-accredited lab showing ≥98% purity, identity confirmation by mass spectrometry, and results for heavy metals and endotoxins within USP limits. “Pharmaceutical grade” without documentation is a marketing claim, not a verified standard.

What is the difference between a research peptide and a compounded peptide?

A compounded peptide is prepared by a licensed pharmacy under state board oversight — and for 503B facilities, under FDA registration — for use in a specific patient with a prescription. A research peptide is produced without those controls, nominally for laboratory use. Using a research-labelled compound for self-injection removes you from every chain of clinical accountability described in this article.

Can a telehealth provider legitimately prescribe peptides?

Yes. Telehealth prescribing of compounded peptides is legal in most US states when conducted by a licensed provider following a genuine clinical evaluation. The format matters far less than the quality and completeness of the evaluation itself.